May 23, 2017 12:35 pm UTC| Business
NOVATO, Calif., May 23, 2017 -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that a Biologics...
May 23, 2017 12:35 pm UTC| Business
NOVATO, Calif., May 23, 2017 -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that a Biologics...
Cytori Logs Final 48 Week Patient Follow Up Visit in Scleroderma Trial
May 23, 2017 12:35 pm UTC| Business
SAN DIEGO, Calif., May 23, 2017 -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) ("Cytori" or the "Company"), today announced that it has now completed all 48 week follow up monitoring visits in its U.S. FDA approved Phase...
Cytori Logs Final 48 Week Patient Follow Up Visit in Scleroderma Trial
May 23, 2017 12:35 pm UTC| Business
SAN DIEGO, Calif., May 23, 2017 -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) ("Cytori" or the "Company"), today announced that it has now completed all 48 week follow up monitoring visits in its U.S. FDA approved Phase...
Cytori Logs Final 48 Week Patient Follow Up Visit in Scleroderma Trial
May 23, 2017 12:35 pm UTC| Business
SAN DIEGO, Calif., May 23, 2017 -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) ("Cytori" or the "Company"), today announced that it has now completed all 48 week follow up monitoring visits in its U.S. FDA approved Phase...
Cytori Logs Final 48 Week Patient Follow Up Visit in Scleroderma Trial
May 23, 2017 12:35 pm UTC| Business
SAN DIEGO, Calif., May 23, 2017 -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) ("Cytori" or the "Company"), today announced that it has now completed all 48 week follow up monitoring visits in its U.S. FDA approved Phase...
Cytori Logs Final 48 Week Patient Follow Up Visit in Scleroderma Trial
May 23, 2017 12:35 pm UTC| Business
SAN DIEGO, Calif., May 23, 2017 -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) ("Cytori" or the "Company"), today announced that it has now completed all 48 week follow up monitoring visits in its U.S. FDA approved Phase...